Want to join the conversation?
Steve Scala of Cowen asks about Sutent long-term outlook, given the competition from immuno-oncology agents. $PFE President Albert Bourla said that the company is confident in its position in the Sutent and Inlyta space. $PFE is studying Inlyta plus other PD-1 inhibitors aggressively to achieve better results than monotherapy in RCC second line.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.